DEC 23, 2018 11:22 PM PST

Buruli ulcer: promising drug for a forgotten disease

WRITTEN BY: Nouran Amin

One of the most forgotten and neglected diseases is Buruli ulcer, a debilitating and stigmatized condition affecting primarily children in West and Central Africa. Buruli ulcer is caused by the bacterium Mycobacterium ulcerans and results in devastating skin lesions leading to permanent disfigurement and long-term disabilities.

Treatment for the disease considers surgical removal of skin lesions as well as antibiotics involving the combination of oral rifampicin and injected streptomycin. However, these treatments come with many limitations. For one, surgery is often not an accessible option especially in in low-income areas. Furtherer, administration of antibiotics requires daily visits to a health center and antibiotic use is often plagued with great side-effects resulting such as hearing loss in over 20% of treated patients. These challenges are pushing researchers to seek safer, accessible, and effective treatment options.

Now, in a study published in Nature Communications, researchers have developed a promising compound against Buruli ulcer. The compound, referred to as Q203 (an imidazopyridine amide), was concluded to be highly effective against Buruli ulcer during in vitro and in vivo studies.

"We were very surprised when we saw this high activity. We had previously screened hundreds of compounds that were originally intended for TB drug development and none of the others showed promising activity against Mycobacterium ulcerans," said Gerd Pluschke, Head of the Molecular Immunology Unit at Swiss TPH. "Q203, however, is even more effective against Buruli ulcer than the current most active antibiotic rifampicin. Such a new and exquisitely effective drug combined with a second antibiotic may result in a considerably shorter oral treatment regimen with fewer adverse side effects."

A promising new drug candidate may improve treatment options of Buruli ulcer patients.

Credit: Hubert Vuagnat via Swiss Tropical and Public Health Institute

What makes Q203 very advantageous for treatment is it has already been tested in a phase I clinical trial for Tuberculous. "That means that as soon as funding can be secured, we will directly test the new compound in Buruli ulcer patients in a phase II trial," says Pluschke.

Source: Swiss Tropical and Public Health Institute

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 26, 2022
Drug Discovery & Development
Sonic Hedgehog gene speeds up large-scale bone regeneration
MAY 26, 2022
Sonic Hedgehog gene speeds up large-scale bone regeneration
Some species of lizards can detach their tails from their bodies when they feel threatened. This common defense mechanis ...
JUN 14, 2022
Cancer
Maintaining Sample Temperature: Q&A From a Corning Scientist
JUN 14, 2022
Maintaining Sample Temperature: Q&A From a Corning Scientist
Generally speaking, bad things can happen when a cell sample temperature gets too hot or too cold. Temperature instabili ...
JUN 14, 2022
Coronavirus
Advances in Latest Coronavirus Research in the 2022 Ongoing Labroots Virtual Event Series
JUN 14, 2022
Advances in Latest Coronavirus Research in the 2022 Ongoing Labroots Virtual Event Series
Labroots hosted its 3rd annual Coronavirus Conference Virtual Event Series on May 4, 2022. The speaker roster for this f ...
JUL 20, 2022
Neuroscience
Stress Transmitter Wakes Up the Sleeping Brain Over 100 Times Per Night
JUL 20, 2022
Stress Transmitter Wakes Up the Sleeping Brain Over 100 Times Per Night
A study published in Nature Neuroscience reported that the stress hormone and transmitter noradrenaline wakes up the hum ...
JUL 21, 2022
Cancer
Can Microrobots Deliver Chemotherapy Directly to a Tumor?
JUL 21, 2022
Can Microrobots Deliver Chemotherapy Directly to a Tumor?
Microrobotics, also called microbotics, is a field of study focusing on miniature robotics capable of carrying tiny comp ...
JUL 23, 2022
Drug Discovery & Development
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
JUL 23, 2022
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
An anti-inflammatory compound has shown promise in treating systemic inflammation and brain injury in patients with seve ...
Loading Comments...